These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 35758639)

  • 21. Selective allosteric modulation of muscarinic acetylcholine receptors for the treatment of schizophrenia and substance use disorders.
    Teal LB; Gould RW; Felts AS; Jones CK
    Adv Pharmacol; 2019; 86():153-196. PubMed ID: 31378251
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Classics in Chemical Neuroscience: Xanomeline.
    Bender AM; Jones CK; Lindsley CW
    ACS Chem Neurosci; 2017 Mar; 8(3):435-443. PubMed ID: 28141924
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Muscarinic M1 and M4 receptor agonists for schizophrenia: promising candidates for the therapeutic arsenal.
    Dean B
    Expert Opin Investig Drugs; 2023; 32(12):1113-1121. PubMed ID: 37994870
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Muscarinic agonists and antagonists in schizophrenia: recent therapeutic advances and future directions.
    Bolbecker AR; Shekhar A
    Handb Exp Pharmacol; 2012; (208):167-90. PubMed ID: 22222699
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Involvement of a subpopulation of neuronal M4 muscarinic acetylcholine receptors in the antipsychotic-like effects of the M1/M4 preferring muscarinic receptor agonist xanomeline.
    Dencker D; Wörtwein G; Weikop P; Jeon J; Thomsen M; Sager TN; Mørk A; Woldbye DP; Wess J; Fink-Jensen A
    J Neurosci; 2011 Apr; 31(16):5905-8. PubMed ID: 21508215
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Muscarinic and nicotinic acetylcholine receptor agonists and allosteric modulators for the treatment of schizophrenia.
    Jones CK; Byun N; Bubser M
    Neuropsychopharmacology; 2012 Jan; 37(1):16-42. PubMed ID: 21956443
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The antipsychotic potential of muscarinic allosteric modulation.
    Bridges TM; LeBois EP; Hopkins CR; Wood MR; Jones CK; Conn PJ; Lindsley CW
    Drug News Perspect; 2010 May; 23(4):229-40. PubMed ID: 20520852
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Muscarinic M1 and/or M4 receptor agonists as potential novel treatments for psychoses].
    Spoelstra SK; Visser L; Knegtering H
    Tijdschr Psychiatr; 2023; 65(9):555-562. PubMed ID: 37947466
    [TBL] [Abstract][Full Text] [Related]  

  • 29. M
    Fu L; Luo Y; Niu L; Lin Y; Chen X; Zhang J; Tang W; Chen Y; Jiao Y
    Bioorg Med Chem; 2024 May; 105():117728. PubMed ID: 38640587
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Allosteric activators of muscarinic receptors as novel approaches for treatment of CNS disorders.
    Digby GJ; Shirey JK; Conn PJ
    Mol Biosyst; 2010 Aug; 6(8):1345-54. PubMed ID: 20582339
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Muscarinic Cholinergic Receptor Agonist and Peripheral Antagonist for Schizophrenia.
    Brannan SK; Sawchak S; Miller AC; Lieberman JA; Paul SM; Breier A
    N Engl J Med; 2021 Feb; 384(8):717-726. PubMed ID: 33626254
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparative analysis of pharmacological properties of xanomeline and N-desmethylclozapine in rat brain membranes.
    Odagaki Y; Kinoshita M; Ota T
    J Psychopharmacol; 2016 Sep; 30(9):896-912. PubMed ID: 27464743
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Novel pharmacological approaches to the treatment of schizophrenia.
    Fink-Jensen A
    Dan Med Bull; 2000 Jun; 47(3):151-67. PubMed ID: 10913983
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Striatal, Hippocampal, and Cortical Networks Are Differentially Responsive to the M4- and M1-Muscarinic Acetylcholine Receptor Mediated Effects of Xanomeline.
    Thorn CA; Moon J; Bourbonais CA; Harms J; Edgerton JR; Stark E; Steyn SJ; Butter CR; Lazzaro JT; O'Connor RE; Popiolek M
    ACS Chem Neurosci; 2019 Mar; 10(3):1753-1764. PubMed ID: 30480428
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Muscarinic acetylcholine receptors: mutant mice provide new insights for drug development.
    Wess J; Eglen RM; Gautam D
    Nat Rev Drug Discov; 2007 Sep; 6(9):721-33. PubMed ID: 17762886
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Attenuation of amphetamine-induced activity by the non-selective muscarinic receptor agonist, xanomeline, is absent in muscarinic M4 receptor knockout mice and attenuated in muscarinic M1 receptor knockout mice.
    Woolley ML; Carter HJ; Gartlon JE; Watson JM; Dawson LA
    Eur J Pharmacol; 2009 Jan; 603(1-3):147-9. PubMed ID: 19111716
    [TBL] [Abstract][Full Text] [Related]  

  • 37. On the unique binding and activating properties of xanomeline at the M1 muscarinic acetylcholine receptor.
    Christopoulos A; Pierce TL; Sorman JL; El-Fakahany EE
    Mol Pharmacol; 1998 Jun; 53(6):1120-30. PubMed ID: 9614217
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evidence of trospium's ability to mitigate cholinergic adverse events related to xanomeline: phase 1 study results.
    Breier A; Brannan SK; Paul SM; Miller AC
    Psychopharmacology (Berl); 2023 May; 240(5):1191-1198. PubMed ID: 37036495
    [TBL] [Abstract][Full Text] [Related]  

  • 39. New and emerging treatments for schizophrenia: a narrative review of their pharmacology, efficacy and side effect profile relative to established antipsychotics.
    Lobo MC; Whitehurst TS; Kaar SJ; Howes OD
    Neurosci Biobehav Rev; 2022 Jan; 132():324-361. PubMed ID: 34838528
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antipsychotic drugs: evolving mechanisms of action with improved therapeutic benefits.
    Dean B; Scarr E
    Curr Drug Targets CNS Neurol Disord; 2004 Jun; 3(3):217-25. PubMed ID: 15180482
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.